Substance / Medication

Mephenytoin

Overview

Active Ingredient
mephenytoin
RxNorm CUI
6757

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

92 trials linked to this intervention

92
Total Trials
17
Recruiting
33
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Incidence and risk factors of posttraumatic epilepsy following pediatric traumatic brain injury: A systematic review and meta-analysis.
Mariajoseph Frederick P, Chen Zhibin, Sekhar Praba et al. · Epilepsia · 2022
PMID: 35996866Meta-AnalysisFull text (PMC)
Tumor Necrosis Factor-α, the Pathological Key to Post-Traumatic Epilepsy: A Comprehensive Systematic Review.
Arulsamy Alina, Shaikh Mohd Farooq · ACS Chem Neurosci · 2020
PMID: 32479057Meta-Analysis
Early and Late Posttraumatic Epilepsy in the Setting of Traumatic Brain Injury: A Meta-analysis and Review of Antiepileptic Management.
Wilson Christopher D, Burks Josh D, Rodgers Richard B et al. · World Neurosurg · 2018
PMID: 29196247Meta-Analysis
Sport-related concussive convulsions: a systematic review.
Kuhl Nicholas O, Yengo-Kahn Aaron M, Burnette Hannah et al. · Phys Sportsmed · 2018
PMID: 29280684Meta-Analysis
[The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
Wang Hong, Nie Yu-qiang, Dai Shou-jun et al. · Zhonghua Nei Ke Za Zhi · 2003
PMID: 14636465Trial
CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He Nan, Yan Feng-Xiang, Huang Song-Lin et al. · Eur J Clin Pharmacol · 2002
PMID: 11956668Trial
P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
Hadama A, Ieiri I, Morita T et al. · Ther Drug Monit · 2001
PMID: 11294510Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mephenytoin (substance)
SNOMED CT
28344001
UMLS CUI
C0025381
RxNorm CUI
6757

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
92
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.